With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. The 2024-25 Innovation Fund Seed Grants are currently open and you...
The Ted Rogers Centre for Heart Research is delighted to welcome Iris Cohn as the new Innovator in Genomic Translation - also recently promoted to Director of the Pharmacogenetics (PGx) Program at The Hospital for Sick Children. A trained pharmacist, Iris established...
NorthMiRs Inc., an innovative cardiovascular biotech start-up, has won $250,000 in funding from the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) PITCH 2024 competition. Since its launch in 2018, the ECHO...
Congenital heart disease (CHD) is the most commonly occurring birth anomaly. Despite a strong genetic basis, almost 90% of cases remain genetically undiagnosed. However, the surge of new technology is enabling a search for hidden gene defects not detectable on...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
3D models of heart failure… stiffened hearts in diabetes…. saving infant lives
After a heart attack, this peptide protects the heart from further injury
Featured Event
ECHO PITCH 2024
Virtual Library
Visit our YouTube channel filled with world-class heart failure educational sessions on diverse topics
All are welcome to join an ECHO webinar on Tuesday June 21, 2022 (11 am – 12 pm EST) featuring Dr. Harry Rowland (CEO and Co-founder, Endotronix).
Dr. Rowland’s presentation entitled, “Insights from the Endotronix Journey: A PMA Medtech “Startup” Story”, will feature an overview of Endotronix, its technologies and the story behind its success. Endotronix is a medical technology company, delivering an integrated platform that provides comprehensive, reimbursable health management innovations for patients suffering from advanced heart failure. Please see attachment for more details.
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).